TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07717905: A Randomized, Double-Blind, Placebo-controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous

Sponsor: Bambusa Therapeutics · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,249,175

Rescue Site Savings

+$3,460,350

Unlock Full NCT07717905 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07717905 Rescue Dossier →